Apex Biotechnology

Apex Biotechnology EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Apex Biotechnology (1733.TW) as of Nov 22, 2026 is 140.73 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 135.28 M TWD — a change of 4.02% (higher).

EBITDA

140.73 MTWD

YoY

4.02%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Apex Biotechnology is 2025 140.73 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Apex Biotechnology was 2024 135.28 M TWD. It decreases by 4.02% higher compared to the previous year.

The Apex Biotechnology EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
256.32 M TWD
Jan 1, 2019
201.48 M TWD
Jan 1, 2020
145.14 M TWD
Jan 1, 2021
216.73 M TWD
Jan 1, 2022
228.79 M TWD
Jan 1, 2023
151.53 M TWD
Jan 1, 2024
135.28 M TWD
Jan 1, 2025
140.73 M TWD
The Apex Biotechnology EBITDA history
YEAREBITDAYoY
140.73 MTWD+4.02%
135.28 MTWD-10.72%
151.53 MTWD-33.77%
228.79 MTWD+5.57%
216.73 MTWD+49.33%
145.14 MTWD-27.96%
201.48 MTWD-21.39%
256.32 MTWD+37.86%
185.92 MTWD-26.55%
253.13 MTWD-15.85%
300.80 MTWD+3.91%
289.49 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apex Biotechnology Stock analysis

What does Apex Biotechnology do? Apex Biotechnology Corp is a Taiwan-based company specializing in the development of innovative biotechnology products. The company was founded in 2002 and offers a wide range of products and services to its customers. Apex Biotechnology Corp began with the production of specialty chemicals and enzymes for research and development purposes. Over the years, the company has expanded its business and focused on the development of diagnostic products, dietary supplements, and pharmaceutical products. The company's business model focuses on the development and marketing of biotechnology products. Apex Biotechnology Corp has established advanced research centers and works closely with research institutions and pharmaceutical companies worldwide to develop innovative solutions. The company operates in various sectors, including diagnostics, dietary supplements, and pharmaceuticals. It offers a diverse range of products, including enzyme immunoassays, lateral flow tests, dietary supplements, and pharmaceuticals. Apex Biotechnology Corp has built strong relationships with research institutions and pharmaceutical companies and has successfully marketed its products internationally. Apex Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Apex Biotechnology stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Apex Biotechnology is 140.73 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Apex Biotechnology changed from 135.28 M TWD to 140.73 M TWD, representing a 4.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Apex Biotechnology since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Apex Biotechnology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Apex Biotechnology

All Key Metrics — Apex Biotechnology